ABSTRACT
OBJECTIVE: To characterize in-hospital outcomes of premature infants diagnosed with severe bronchopulmonary dysplasia (BPD). STUDY DESIGN: Retrospective cohort study including premature infants with severe BPD discharged from 348 Pediatrix Medical Group neonatal intensive care units from 1997 to 2015. RESULTS: There were 10 752 infants with severe BPD, and 549/10 752 (5%) died before discharge. Infants who died were more likely to be male, small for gestational age, have received more medical interventions and more frequently diagnosed with surgical necrotizing enterocolitis, culture-proven sepsis and pulmonary hypertension following 36 weeks of postmenstrual age compared with survivors. Approximately 70% of infants with severe BPD were discharged by 44 weeks of postmenstrual age, and 86% were discharged by 48 weeks of postmenstrual age. CONCLUSIONS: A majority of infants diagnosed with severe BPD were discharged home by 44 weeks of postmenstrual age. These results may inform discussions with families regarding the expected hospital course of infants diagnosed with severe BPD.
Subject(s)
Bronchopulmonary Dysplasia/physiopathology , Enterocolitis, Necrotizing/epidemiology , Hypertension, Pulmonary/epidemiology , Sepsis/epidemiology , Bronchopulmonary Dysplasia/complications , Electronic Health Records , Enterocolitis, Necrotizing/surgery , Female , Gestational Age , Humans , Infant , Infant, Extremely Low Birth Weight , Infant, Extremely Premature , Infant, Newborn , Infant, Small for Gestational Age , Intensive Care Units, Neonatal , Male , North Carolina , Patient Discharge , Retrospective Studies , Risk Factors , Sepsis/diagnosis , Sex FactorsABSTRACT
The definition of hypoglycemia in the newborn infant has remained controversial because of lack of significant correlation between plasma glucose concentration, clinical symptoms, and long-term sequelae. A threshold value for plasma glucose at which clinical intervention should be considered is important because of the potential for serious neurological injury. In this review, we have described threshold values for plasma glucose in the newborn infant, based upon available data, at which the clinician should consider close monitoring and therapeutic interventions aimed at increasing the glucose level. In clinically symptomatic infants, plasma glucose concentrations of 45 mg/dL (2.5 mmol/L) or less should be considered as threshold for intervention. In an asymptomatic baby and in those at risk for hypoglycemia, irrespective of gestational and postnatal age, plasma glucose values less than 36 mg/dL (2.0 mmol/L) should be considered as threshold levels. Variances from these criteria, as in breast-fed infants, are discussed. The threshold values described for surveillance and intervention should be separated from the targeted therapeutic values which should be in the range of 72-90 mg/dL (4-5 mmol/L).
